Medical Disclaimer The information provided on this page is for educational and informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment
Sri Lanka Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market (2026-2032) | Share, Outlook, Analysis, Growth, Value, Forecast, Industry, Companies, Size & Revenue, Segmentation, Competitive Landscape, Trends Market Forecast By GLP-1 Receptor Agonists (Exenatide, Liraglutide (Victoza), Lixisenatide (Lyxumia), Dulaglutide (Trulicity), Semaglutide (Ozempic)), By Insulin Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, Biosimilar Insulins) And Competitive Landscape Sri Lanka import trend for insulin drugs and GLP-1 receptor agonists showed significant growth, with a 43.03% increase from 2023 to 2024
August 18, 2023
Gilead and Regeneron both announced deals with the Trump administration that included TrumpRx discounts and still have no drugs on the site
21 FilipiB.GradinikL.RiharK.ooE.PereyraA.PotokarJ